Immune Effects

WFA's immune relevance extends beyond direct tumour-cell killing. The most important work so far suggests that it can reduce immunosuppressive myeloid signalling, promote more favourable immune infiltration, and sensitise some tumours to checkpoint blockade.

This evidence is still preclinical. No completed human trial has defined WFA's immune effects in cancer patients.

State of the evidence

Most immune data comes from mechanistic work and animal models. The strongest translational signal comes from syngeneic lung cancer models where WFA improved response to anti-PD-L1 therapy.

That makes the immune story promising, not settled.

MDSC and tumour-associated macrophage modulation

Myeloid-derived suppressor cells and tumour-associated macrophages are central to tumour immune evasion.

WFA reduces MDSC production of IL-10 and reactive oxygen species. Those changes matter because MDSCs often suppress T-cell function through oxidative and cytokine-mediated mechanisms.

WFA also reduces macrophage secretion of IL-6 and TNF-α, which can otherwise reinforce an immunosuppressive microenvironment.

CD4+ and CD8+ T-cell effects

In a murine mammary tumour model, oral WFA reduced tumour burden and increased intratumoural and splenic CD4+ helper T-cell proportions.

In a syngeneic NSCLC model, WFA increased CD8+ T-cell infiltration when paired with anti-PD-L1 therapy. That combination exceeded either agent alone.

The exact T-cell pattern may be model-dependent, but the direction of effect supports immune microenvironment reshaping rather than simple immune suppression.

Checkpoint inhibitor sensitisation

This is the most clinically interesting immune mechanism so far.

WFA induces immunogenic cell death in NSCLC models. That means tumour-cell death is accompanied by danger signalling that can activate dendritic cells and promote adaptive immune engagement.

WFA also increases tumour-cell PD-L1 expression through ROS-mediated signalling. On its own, that can look counterintuitive. In the right context, it may increase tumour susceptibility to anti-PD-L1 therapy.

That is what has been observed in mouse models. WFA sensitised an otherwise resistant lung cancer model to anti-PD-L1 treatment without additional weight loss or obvious toxicity.

Dendritic cells

In vitro work supports dendritic cell activation downstream of WFA-induced immunogenic cell death. This strengthens the checkpoint-sensitisation rationale.

Neutrophils

No peer-reviewed evidence currently defines WFA's effect on tumour-associated neutrophils. This remains a meaningful gap.

Summary of immune evidence status

Immune cell or effect	Evidence level
MDSC suppression (`IL-10`, ROS)	Mechanistic and in vitro confirmed
TAM cytokine modulation (`IL-6`, `TNF-α`)	Mechanistic and in vitro confirmed
`CD4+` T-cell increase in tumour	Animal-supported
`CD8+` T-cell increase in combination therapy	Animal-supported
Immunogenic cell death induction	In vitro confirmed and animal-supported
Checkpoint inhibitor sensitisation	Animal-supported
Dendritic cell activation	In vitro confirmed
Human immune data	None available

Clinical take

WFA's immune profile is interesting because it may help in two ways at once. It can reduce tumour-intrinsic survival signalling and weaken parts of the suppressive microenvironment around the tumour.

The most credible combination use case at present is with checkpoint blockade, especially in tumours where baseline resistance is driven by poor immune activation and suppressive myeloid tone.

Key references

Noh K. H. et al. — MDSC and macrophage modulation, including reduced myeloid suppressor function with WFA.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11028968/

Oral Administration of Withaferin A Increases Infiltration of CD4+ T Cells and Reduces Tumor Burden in a Mouse Mammary Tumor Model — CD4+ T-cell changes with oral WFA in breast cancer.
https://pdfs.semanticscholar.org/6cd9/3d0c62425082f139be24a17401fc12d71626.pdf

Banerjee S. et al. — immunogenic cell death, PD-L1 up-regulation, and checkpoint sensitisation in NSCLC.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10295988/

Qiao J. et al. — WFA as a phytochemical checkpoint sensitiser in the broader ICI literature.
https://onlinelibrary.wiley.com/doi/10.1002/ptr.8482

Singh N. et al. — broader overview of WFA and Withania somnifera immunomodulatory actions.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6862083/

Access and availability:
Source: MCS Formulas, “Withaferin A Pro Liposomal.”
50 mg WFA per capsule. Available via healthcare professional request.
https://www.mcsformulas.com/vitamins-supplements/withaferin-a-pro-liposomal/ref/14